Ceplene is a medicine used in combination with interleukin-2 (a cancer medicine) as maintenance treatment in adults with acute myeloid leukaemia (AML), a type of cancer affecting the white blood cells. It is used during the patients’ first ‘remission’ (a period without symptoms of the disease after the first course of treatment). AML is rare, and Ceplene was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 11 April 2005. Ceplene contains the active substance histamine dihydrochloride.
Therapeutic Indication
### Therapeutic indication Ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (IL-2). The efficacy of Ceplene has not been fully demonstrated in patients older than age 60.
Therapeutic Area (MeSH)
ATC Code
L03AX14
ATC Item
histamine dihydrochloride
Pharmacotherapeutic Group
Immunostimulants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Histamine dihydrochloride | N/A | 磷酸组胺 |
EMA Name
Ceplene
Medicine Name
Ceplene
Aliases
N/ANo risk management plan link.
